<DOC>
	<DOCNO>NCT02316496</DOCNO>
	<brief_summary>The main objective study evaluate objective response rate two month ( complete disappearance disease partial disappearance disease ) obtain administration combination therapy cetuximab irinotecan patient metastatic colorectal cancer . Secondaries objective assess progression-free survival , overall survival , toxicity , quality life .</brief_summary>
	<brief_title>Rechallenge Cetuximab Combined With Irinotecan Third-line Chemotherapy Patients With Metastatic Colorectal Cancer - Phase II Study</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Signed date informed consent Histologically confirm metastatic adenocarcinoma colon rectum All Wild Type KRAS ( exon 2 [ codon 1213 ] , exon 3 [ codon 61 ] ; exon 4 [ codon 146 ] ) , NRAS ( exon 2 [ codon 1213 ] exon 3 [ codon 61 ) BRAF ( V600E ) tumor ( local assessment perform either primary tumor metastasis ) First line chemotherapy regimen fluoropyrimidine Irinotecan ( FOLFIRI ) + cetuximab initial partial complete response progressive disease ( PD ) PD ≤ 6 week last administration cetuximab Other line ( ) therapy ( y ) include follow drug : second line oxaliplatin base chemotherapy fluoropyrimidines ( 5FU capecitabine ) + bevacizumab eventually regorafenib ( possible mandatory ) progression limit toxicity last therapy minimum 4 month last injection cetuximab inclusion study At least one measurable lesion ≥ 10 mm assess CTscan MRI ( Magnetic Resonance Imaging ) accord RECIST v1.1 ( All site must evaluate ≤ 28 day prior enrolment ) Age ≥18 year World Health Organization ( WHO ) Performance status ( PS ) 02 The patient adequate organ function , define : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L , hemoglobin ≥ 9 g/dL , platelet ≥ 100 x 109/L.Total bilirubin ≤ 1.5 time upper limit normal value ( ULN ) , serum alkaline phosphatase level &lt; 5 time ULN , Serum creatinine level &lt; 150μM/l For female patient childbearing potential , negative pregnancy test within 7 day start study drug Men woman require use adequate birth control study ( applicable ) 6 month end study treatment Registration national health care system ( CMU include ) Previous chemotherapy adjuvant therapy different combination schedule first second line treatment Presence KRAS , BRAF NRAS mutation allelic discrimination tumor DNA Significant cardiovascular disease include unstable angina myocardial infarction within 12 month initiation study treatment history ventricular arrhythmia ( treat ) History evidence central nervous system metastasis ( systematic CTscan MRI mandatory clinical symptom ) Known allergy hypersensitivity cetuximab Previous concurrent malignancy except basal squamous cell skin cancer , situ carcinoma cervix , lowrisk prostate cancer accord d'Amico classification solid tumor treat curatively without evidence recurrence least 5 year prior study Active uncontrolled clinically serious infection Known human immunodeficiency virus ( HIV ) infection acquire immunodeficiency syndrome ( AIDS ) relate illness Other serious uncontrolled nonmalignant disease Pregnancy Breast feeding Treatment investigational medicinal product within 28 day prior study entry Known Gilbert 's syndrome Concomitant administration live , attenuate virus vaccine yellow fever vaccine Concomitant use St John 's Wort Chronic inflammatory bowel disease and/or Bowel obstruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Colorectal</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Thrid-line</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Cetuximab</keyword>
</DOC>